Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: An overview

Circulation Research

Volumn 90, Issue 1, 2002, Pages 21-28

  Ignarro, Louis J ^a   Napoli, Claudio ^a   Loscalzo, Joseph ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular pharmacology; Endothelium; Nitric oxide; Oxidant stress; Vascular type

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ACETYLSALICYLIC ACID 4 NITROXYBUTYL ESTER; AMYL NITRITE; ARGININE; ASCORBIC ACID; CARDIOVASCULAR AGENT; DICLOFENAC DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROXAN DERIVATIVE; GLYCERYL TRINITRATE; HYDRALAZINE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; LINSIDOMINE; MOLSIDOMINE; N ACETYL S NITROSOPENICILLAMINE; NICORANDIL; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; S NITROSOALBUMIN; S NITROSODICLOFENAC; S NITROSOGLUTATHIONE; SODIUM TRIOXODINITRATE; SPERMINE DERIVATIVE; SYDNONIMINE DERIVATIVE; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CARDIOVASCULAR SYSTEM; DRUG ACTIVATION; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR SYSTEM; HUMANS; MODELS, BIOLOGICAL; NITRIC OXIDE; NITRIC OXIDE DONORS;

EID: 0037059510     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/hh0102.102330     Document Type: Review

References (102)

1. Nitric oxide as a signaling molecule in the vascular system: An overview
2. Interactions between NO and reactive oxygen species: Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure
3. Nitric oxide insufficiency, platelet activation, and arterial thrombosis
4. What we know and don't know about L-arginine and NO
5. Nitric oxide and atherosclerosis
6. Biological aspects of reactive nitrogen species
7. Nitric oxide signalling: Would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone?
8. Biochemistry of nitric oxide and its redox-activated forms
9. Nitroglycerine, the first one hundred years: New facts about an old drug
10. The use of inhaled nitric oxide in a wide variety of clinical problems
11. P-Nitrophosphate compounds: New N-O heterodienophiles and nitroxyl delivery agents
12. Differential actions of L-cysteine on responses to nitric oxide, nitroxyl anions and EDRF in the rat aorta
13. "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: Convenient nitric oxide dosage forms
14. Neuroprotective effects of DETA-NONOate, a nitric oxide donor, on hydrogen peroxide-induced neurotoxicity in cortical neurons
15. Diazeniumdiolates: Pro- and antioxidant applications of the "NONOates"
16. Aerosolized soluble nitric oxide donor improves oxygenation and pulmonary hypertension in acute lung injury
17. Heterocyclic NO prodrugs
18. The use of nitric oxide donors in pharmacological studies
19. S-Nitrosothiols do not include oxidative stress, contrary to other nitric oxide donors, in cultures of vascular endothelial or smooth muscle cells
20. S-Nitrosothiols
21. Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide
22. Nitrosylated bovine serum albumin derivatives as pharmacologically active nitric oxide congeners
23. Nonenzymatic nitric oxide synthesisin biological systems
24. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine
25. Coronary arterial relaxation and guanylate cyclase activation by cigarette smoke, N′-nitrosonomicotine and nitric oxide
26. Relationship between cyclic guanosine 3′,5′-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: Effects of methylene blue and methemoglobin
27. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction
28. On the use of nitrite of amyl in angina pectoris
29. Nitroglycerine as a remedy for angina pectoris
30. Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells
31. Inhibition of NADPH-cytochrome P450 reductase and glyceryl trinitrate biotransformation by diphenyleneiodonium sulfate
32. - formation
33. Sulfhydryl requirement for relaxation of vascular smooth muscle
34. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin
35. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: A novel mechanism underlying tolerance and cross-tolerance
36. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: A new action for an old drug
37. Urinary nitrotyrosine content as a marker of peroxynitrite-induced tolerance to organic nitrates
38. Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta
39. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-modiated superoxide production, and vascular NO bioavailability
40. Folate and nitrate-induced endothelial dysfunction
41. Depletion of intracellular glutathione reduces mutations by nitric oxide-donating drugs
42. S-Nitrosocaptopril, I: Molecular characterization and effects on the vasculature and on platelets
43. The hemodynamic effects of S-nitrosocaptopril in anesthetized dogs
44. Gastric toxicity of antiplatelet therapy with low-dose aspirin
45. Aspirin
46. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide
47. Nitric oxide: A physiological messenger
48. Intrahepatic modulation of portal pressure and its role in portal hypertension
49. Role of nitric oxide in pathogenesis of aspirin-induced gastric mucosal damage in rats
50. The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs
51. NO aspirins: Antithrombotic activity of derivatives of acetylsalicylic acid releasing nitric oxide
52. NO-aspirins, a class of new-inflammatory and anti-thrombotic agents
53. Nitrosothiol esters of diclofenac synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs
54. Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: Role of neutrophils
55. Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats
56. In vitro study of the anti-aggregating activity of two nitroderivatives of acetylsalicylic acid
57. The antiplatelet effects of a new nitroderivative of acetylsalicylic acid: An in vitro study of inhibition on early phase of platelet activation and on TXA2 production
58. In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX 4016
59. Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid
60. Prevention of pulmonary thromboembolism by NCX4016, a nitric oxide-releasing aspirin
61. Nitroaspirin (NCX 4016) reduces brain damage induced by focal cerebral ischemia in rat
62. Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice
63. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation
64. Local drug delivery: An emerging approach in the treatment of restenosis
65. Biocompatibility aspects of new stent technology
66. Incorporation of nitric oxide-releasing crosslinked polyethylenimine microspheres into vascular grafts
67. Nitric oxide-releasing polymers containing the [N(O)NO]- group
68. S-Nitrosylation of proteins with nitric oxide: Synthesis and characterization of biologically active compounds
69. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide
70. The potent platelet inhibitory effects of S-nitrosated albumin coating of artificial surfaces
71. In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols
72. Endothelial dysfunction: From physiology to therapy
73. Bradykinin metabolism in the isolated perfused rabbit heart
74. Endothelial dysfunction and inhibition of converting enzyme
75. Vascular protection with newer antihypertensive agents
76. Role of nitric oxide in the control of renin secretion
77. Angiotensin II-mediated hypertension in the rate increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alterations in vasomotor tone
78. Interactions among ACE, kinins and NO
79. Dual mode of action of dihydropyridine calcium antagonists: A role for nitric oxide
80. Nifedipine and nisoldipine modulate membrane potential of vascular endothelium via a myo-endothelial pathway
81. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric oxide synthase expression
82. Pranidipine enhances the action of nitric oxide released from endothelial cells
83. Simvastatin improves coronary endothelial function independent of lipid lowering
84. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase
85. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
86. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease
87. Direct vascular effects of HMG-CoA reductase inhibitors
88. Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase
89. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
90. Molecular multitasking: Statins lead to more arteries, less plaque
91. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals
92. Experimental evidence of selective antagonistic action of nebivolol on β-1-adrenergic receptors
93. Nebivolol induces endothelium-dependent relaxations of canine arteries
94. Nitric oxide mediated venodilator effect of nebivolol
95. Nebivolol vasodilates human forearm vasculature: Evidence for an L-arginine/NO-dependent mechanism
96. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission
97. Overall cardiovascular profile of sildenafil citrate
98. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina
99. Sex and the patient with cardiovascular risk factors: Focus on sildenafil
100. A heterogeneous population of 1 adrenergic receptor mediates contraction of human corpus cavernosum smooth muscle to norepinephrine
101. Design and evaluation of nitrosylated-adrenergic receptor antagonists as potential agents for the treatment of impotence